Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]).

Author information

Affiliations

  • 1. Department of Pediatrics, Division of Immunology and Allergy, UCLA School of Medicine, Los Angeles, CA 90095, USA.
      Authors
    • Kobayashi RH 1
    (1 author)
  • 2. Pediatric Pulmonary Associates of North Texas, Frisco, TX 75034, USA.
      Authors
    • Mandujano JF 2
    (1 author)
  • 3. Asthma & Allergy Center, Inc., Toledo, OH 43617, USA.
      Authors
    • Rehman SM 3
    (1 author)
  • 4. Midlands Pediatrics, Papillion, NE 68046, USA.
      Authors
    • Kobayashi AL 4
    (1 author)
  • 5. Divisions of Adult and Pediatric, Allergy and Immunology, University of California-San Diego, La Jolla, CA 92093, USA.
      Authors
    • Geng B 5
    (1 author)
    • Show all (9)

ORCIDs linked to this article

Immunotherapy, 06 May 2021, 13(10):813-824
https://doi.org/10.2217/imt-2021-0064 PMID: 33955240 

Abstract 

Background: Subcutaneous human immunoglobulin (16.5%; octanorm/cutaquig®) was efficacious and well tolerated in patients with primary immunodeficiencies in a Phase III study. A subanalysis of pediatric data is presented here. Materials & methods: Children (2-16 years) previously treated with intravenous human immunoglobulin received weekly subcutaneous human immunoglobulin infusions over 64 weeks. The main objective was to assess the efficacy of cutaquig in preventing serious bacterial infections. Results: 38 children received 2213 infusions of cutaquig. No serious bacterial infections developed during the study. The rate of other infections was 3.1 per person-year and the rate of adverse drug reactions was 0.083 per infusion. Higher immunoglobulin G trough levels were achieved with cutaquig compared with previous intravenous therapy. Conclusion: Once-weekly infusions of cutaquig were efficacious and well tolerated in children with primary immunodeficiencies.

Full text links 

Read article at publisher's site: https://doi.org/10.2217/imt-2021-0064

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Octapharma